ENDOGENOUS PAI-1 IS PATHOGENIC IN EXPERIMENTAL DIABETIC NEPHROPATHY

被引：0
|
作者：
Lassila, M. [1 ]
Fukami, K. [1 ]
Jandeleit-Dahm, K. [1 ]
Semple, T. [2 ]
Carmeliet, P. [3 ]
Cooper, M. E. [1 ]
Kitching, A. R. [2 ]
机构：
[1] Baker Heart Res Inst, Melbourne, Vic, Australia
[2] Monash Univ, Dept Med, Clayton, Vic 3800, Australia
[3] Flanders Interuniv Inst Biotechnol, Louvain, Belgium
来源：
NEPHROLOGY | 2006年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A27 / A28
页数：2
相关论文
共 50 条
  • [41] Elevation of PAI-1 expression and growth characteristics of diabetic oral mucosal fibroblasts
    Boucree, TS
    Akhondzadeh, A
    Qunzhou, Z
    Wu, Y
    Nguyen, T
    Le, AD
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 270A - 270A
  • [42] Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides
    Muehlenweg, B
    Guthaus, E
    de Prada, NA
    Schmitt, M
    Schmiedeberg, N
    Kotzsch, M
    Creutzburg, S
    Kramer, MD
    Kessler, H
    Wilhelm, OG
    Magdolen, V
    THROMBOSIS RESEARCH, 2000, 98 (01) : 73 - 81
  • [43] TOTAL PAI-1, ACTIVE PAI-1 AND T-PA-PAI COMPLEX IN LIVER AND ISCHEMIC HEART-DISEASES
    YASUMURO, Y
    SUZUKI, S
    AKIYAMA, Y
    SHIMAZU, C
    KUWAHARA, C
    KAZAMA, M
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1272 - 1272
  • [44] Mechanistic Studies on the Inactivation of Plasminogen Activator Inhibitor (PAI-1) by PAI-749, a Small Molecule PAI-1 Antagonist
    Gardell, S.
    Antrilli, T.
    Elokdah, H.
    Krueger, J.
    Mayer, S.
    Orcutt, S.
    Vlasuk, G.
    Crandall, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 169 - 169
  • [45] Advanced glycation is an important pathogenic process in experimental diabetic nephropathy.
    Soulis, T
    Sastra, S
    Thallas, V
    Berka, J
    McWilliam, B
    MurrayMcIntosh, RP
    Gilbert, R
    Neale, TJ
    Jerums, G
    Cooper, ME
    KIDNEY INTERNATIONAL, 1996, 50 (04) : 1415 - 1415
  • [46] PAI-1 polymorphism and expression of uPA, PAI-1 and COX-2 in breast cancer.
    Minisini, AM
    Di Loreto, C
    Pestrin, M
    Fabbro, D
    Cardellino, GG
    Russo, S
    Andreetta, C
    Damante, G
    Piga, A
    Puglisi, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 879S - 879S
  • [47] Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo
    Daniel, C
    Hering, K
    Lawler, J
    Hugo, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V236 - V236
  • [48] Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1
    Van De Craen, Britt
    Scroyen, Ilse
    Vranckx, Christine
    Compernolle, Griet
    Lijnen, H. Roger
    Declerck, Paul J.
    Gils, Ann
    THROMBOSIS RESEARCH, 2012, 129 (04) : E126 - E133
  • [49] Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women
    Mertens, I
    Van der Planken, M
    Corthouts, B
    Wauters, M
    Peiffer, F
    De Leeuw, I
    Van Gaal, L
    HORMONE AND METABOLIC RESEARCH, 2001, 33 (10) : 602 - 607
  • [50] Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients
    Chi, Y. F.
    Chai, J. K.
    Yu, Y. M.
    Luo, H. M.
    Zhang, Q. X.
    Feng, R.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03): : 10081 - 10086
12345